Compare Panacea Biotech with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs WYETH LTD - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH WYETH LTD PANACEA BIOTECH/
WYETH LTD
 
P/E (TTM) x 12.1 27.7 43.7% View Chart
P/BV x 2.9 5.3 54.4% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 PANACEA BIOTECH   WYETH LTD
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
WYETH LTD
Mar-13
PANACEA BIOTECH/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs3641,044 34.9%   
Low Rs129818 15.8%   
Sales per share (Unadj.) Rs96.8298.6 32.4%  
Earnings per share (Unadj.) Rs-12.457.2 -21.7%  
Cash flow per share (Unadj.) Rs-2.958.4 -4.9%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.8 0.0%  
Book value per share (Unadj.) Rs50.4249.5 20.2%  
Shares outstanding (eoy) m61.2522.72 269.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.53.1 81.7%   
Avg P/E ratio x-19.916.3 -122.1%  
P/CF ratio (eoy) x-86.415.9 -542.2%  
Price / Book Value ratio x4.93.7 131.1%  
Dividend payout %029.7 0.0%   
Avg Mkt Cap Rs m15,10121,157 71.4%   
No. of employees `0002.50.5 501.6%   
Total wages/salary Rs m1,516400 379.0%   
Avg. sales/employee Rs Th2,401.913,787.4 17.4%   
Avg. wages/employee Rs Th614.2813.0 75.5%   
Avg. net profit/employee Rs Th-307.92,643.3 -11.6%   
INCOME DATA
Net Sales Rs m5,9286,783 87.4%  
Other income Rs m82353 23.3%   
Total revenues Rs m6,0107,136 84.2%   
Gross profit Rs m8451,617 52.3%  
Depreciation Rs m58527 2,200.4%   
Interest Rs m1,0066 18,287.3%   
Profit before tax Rs m-6641,938 -34.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m99632 15.6%   
Profit after tax Rs m-7601,301 -58.4%  
Gross profit margin %14.323.8 59.8%  
Effective tax rate %-14.932.6 -45.6%   
Net profit margin %-12.819.2 -66.9%  
BALANCE SHEET DATA
Current assets Rs m5,6036,984 80.2%   
Current liabilities Rs m6,9102,056 336.1%   
Net working cap to sales %-22.072.6 -30.3%  
Current ratio x0.83.4 23.9%  
Inventory Days Days20699 207.3%  
Debtors Days Days8424 349.8%  
Net fixed assets Rs m9,941244 4,069.1%   
Share capital Rs m61227 27.0%   
"Free" reserves Rs m3,0265,441 55.6%   
Net worth Rs m3,0875,668 54.5%   
Long term debt Rs m5,70725 22,828.4%   
Total assets Rs m16,0767,901 203.5%  
Interest coverage x0.3353.3 0.1%   
Debt to equity ratio x1.80 41,916.3%  
Sales to assets ratio x0.40.9 43.0%   
Return on assets %1.516.5 9.3%  
Return on equity %-24.622.9 -107.3%  
Return on capital %3.934.0 11.5%  
Exports to sales %24.00.2 11,012.5%   
Imports to sales %17.536.3 48.3%   
Exports (fob) Rs m1,42415 9,623.6%   
Imports (cif) Rs m1,0402,465 42.2%   
Fx inflow Rs m1,60015 10,526.5%   
Fx outflow Rs m1,1312,677 42.3%   
Net fx Rs m469-2,662 -17.6%   
CASH FLOW
From Operations Rs m1,180923 127.8%  
From Investments Rs m553317 174.5%  
From Financial Activity Rs m-1,644-481 341.7%  
Net Cashflow Rs m90759 11.8%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 0.6 11.3 5.3%  
FIIs % 1.3 7.2 18.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 30.4 77.6%  
Shareholders   10,259 21,978 46.7%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 642 Points; Automobile and Realty Stocks Plunge(Closing)

Indian share markets fell sharply today amid fears of rising crude oil prices and weakness in the rupee rattled investor sentiment.

Related Views on News

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 17, 2019 03:35 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - GLENMARK PHARMA COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS